Accéder au contenu
Merck

Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.

Current medical research and opinion (2005-06-23)
Gerd Bönner, Winfried Fuchs
RÉSUMÉ

Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan has the property to maintain a sustained blood pressure reduction for up to 48 h after dosing. Since lack of compliance is a known problem in patients with hypertension, these findings could be of particular clinical relevance.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Candesartan cilexetil, ≥98% (HPLC)
Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard